Konstantinos Efthymiopoulos, PhD, MBA
Dr. Efthymiopoulos is currently the Executive Chairman of Eporgen Life Sciences SpA and the Managing Director of PLUS Life Sciences Consulting Sàrl. From his international career of over 25 years in big pharma and biotech, he acquired hands-on experience that spans research to clinical development and product launch. Recent appointments include CEO of Funxional Therapeutics (anti-inflammatory assets sold to Boehringer Ingelheim), an Advisor to Index Ventures, the CSO and Head of R&D at Eurand and the Corporate VP-Head of the Dermatology business unit of Serono. He holds a Ph.D. in Pharmacokinetics and M.Sc. degrees in Pharmacology and Industrial Pharmacy from the University of Strasbourg as well as an MBA from London Business School.
Simon Nebel, PhD, MBA
Since joining Aravis in 2001, Simon Nebel has participated in the financing of a number of life science companies and the M&A transactions of a number of Aravis portfolio companies. Most recently he was a co-founder of Aravis Energy I LP, the first Swiss Limited Partnership focused on renewable energy.
Before joining Aravis, Simon was a group strategist at UBS (London, Basel and Zurich), where he coordinated and worked on business planning and modelling. This included developing a Biotechnology Venture Capital business proposal for UBS Capital.
He is currently a board member of Synaffix (NL), MarinoMed (AT), RuiYi Inc. (USA/China), and Leading Swiss Renewable Energy AG and a former member of the board of directors of Borean Pharma (Denmark), ImVision (Switzerland), MerLion Pharmaceutical SA (Switzerland) and secretary of the board of Evolva (Switzerland).
Simon holds a PhD in Biophysics from the Biocentre of the University of Basel (1996) and an MBA with distinction from the London Business School (2001).
Edward van Wezel
Edward is managing partner and founder of BioGeneration Ventures. He has extensive international expertise in small and large pharma and biotech companies and currently serves on the boards of NovioGendix, Progentix Orthobiology, Cristal Therapeutics and Acerta Pharma as well as BioCeros until it was sold in 2011. Edward started his industrial career as process engineer for Chiron Inc. and working for Johnson & Johnson as project manager, where was responsible for preclinical and Phase II oncology development projects and was involved in in-licensing activities. Since 2000, he gained experience in several small start-up and early stage companies in the Netherlands. He was director of business development at Pepscan Systems and managing director of Macrozyme, until the formation of a successful partnership with Genzyme Inc. in 2005. Edward holds a MSc in chemistry from the University of Utrecht and a MSc in biochemical engineering from the Delft University of Technology.
Hakan Goker, PhD
Hakan is a senior investment director at Merck Ventures, the corporate venture capital fund of Merck. Hakan joined Merck Ventures in 2013 and previously was investing as a partner at Aescap Venture and prior to that at Atlas Venture. Since 2006, Hakan was instrumental in the creation, financing, and strategy of multiple biotechnology companies globally including Forendo (FI), Orphazyme (DK), F Star (NL), Bicycle Therapeutics (UK), Nimbus Discovery (US) and Nitec now Horizon Pharma (CH/US). Hakan received his PhD in cancer biology from the Institute of Cancer Research University of London and continued his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his BSc Honours, from University College London. Hakan is a board member of Forendo Pharma, Synaffix, Asceneuron, Raze Therapeutics, Tocopherx, and Progyny Inc.